Biopharma Quarterly Dealmaking Statistics, Q3 2016
Biopharma Quarterly Dealmaking Statistics, Q3 2016
$499.00
A look at biopharma financing, M&A and alliance activity July–September 2016, based on data from Strategic Transactions.
Publisher: In Vivo
- Description
- Contents
- Samples
In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in m&as was allergan’s buying spree, including two nash companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.
EXECUTIVE SUMMARY
In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in m&as was allergan’s buying spree, including two nash companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.
Exhibit 1: Q3 2016 Biopharma Financing: $ raised
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Pacts in Medtech 
Sign up to the